Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Endometrioid × temsirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 13 Neoplasm Metastasis 11 Glioblastoma 7 Prostatic Neoplasms 6 Neoplasms 6 Kidney Neoplasms 6 Brain Neoplasms 6 Sarcoma 5 Carcinoma, Hepatocellular 5 Ovarian Neoplasms 4 Glioma 4 Endometrial Neoplasms 4 Central Nervous System Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 4 Advanced Cancer 4 Uterine Cervical Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Oligodendroglioma 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Liver Neoplasms 3 Colorectal Neoplasms 3 Astrocytoma 3 Urinary Bladder Neoplasms 2 Thyroid Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2

Interventions

temsirolimus 1 sintilimab 1 pembrolizumab 1 palbociclib 1 olaparib 1 durvalumab 1 defactinib 1 ceralasertib 1 Therapeutics 1 Restraint, Physical 1 Radiation, Ionizing 1 RO5126766 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1 Hysterectomy 1 Fulvestrant 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02093598 2020-11-27

POEM

MedSIR

Phase 2 Completed

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡